LKQ Corp (LKQ) Q2 2026 earnings review
North American Growth Eclipsed by European ERP Collapse and Slashed Guidance
LKQ's Q2 paints a deeply polarized picture. North America broke a nine-quarter losing streak to post positive organic growth (+0.5%), fueled by record alternative-parts utilization. However, this hard-fought win was entirely overshadowed by a severe deceleration in Europe, where organic revenue collapsed 12.6% due to a poorly executed ERP migration in Germany and sluggish UK/Benelux demand. More concerning is the universal margin compression: even growing segments (North America and Specialty) saw steep EBITDA margin declines, proving volume growth is currently failing to offset inflation and pricing pressures. Consequently, management aggressively slashed full-year 2026 guidance across every major metric, reversing the 'gradual recovery' narrative set just one quarter ago.
🐂 Bull Case
The core North American business has finally stabilized, posting its first positive organic revenue growth (+0.5%) in nine quarters, outperforming a still-fragile repairable claims market.
Management observed moderating insurance premiums turning negative in May and June, which acts as a primary catalyst for improving repairable claims and reducing total loss rates.
🐻 Bear Case
Europe EBITDA margins compressed drastically from 9.4% to 7.5%, driven by internal IT execution failures (Germany ERP) and weak baseline demand.
Despite Specialty and North America growing revenues, their EBITDA margins shrank by 180 bps and 140 bps respectively. Top-line beats are no longer protecting the bottom line.
⚖️ Verdict: 🔴
Bearish. While North America's stabilization is a critical milestone, the systemic margin decay across all divisions and the severe downward revision of full-year cash flow and EPS guidance reflect a company struggling to maintain its operating leverage.
Key Themes
German ERP Migration Derails Europe
Europe, historically a key pillar of LKQ's turnaround story, saw organic revenue decelerate violently by 12.6% YoY. Management cited a major ERP implementation in Germany as the primary culprit. While IT migrations often cause temporary friction, a double-digit organic drop suggests catastrophic near-term business disruption. Furthermore, underlying demand remains weak, with management citing lower volumes in the UK and Benelux regions.
Volume Growth Fails to Protect Margins
A specific data point completely contradicts LKQ's positive volume narrative: North America achieved +0.5% organic revenue growth, yet its Segment EBITDA margin fell from 15.5% to 14.1%. Similarly, Specialty grew organic revenue by 4.5%, but its EBITDA margin collapsed from 8.5% to 6.7%. This negative operating leverage suggests severe pricing constraints or rising input/tariff costs that management is unable to pass through.
Record Alternative-Parts Utilization (APU)
A major technological and operational win for the quarter was achieving record alternative-parts utilization (APU) of over 40% in North America. This increased penetration, particularly with Multi-Shop Operators (MSOs), is the direct engine that drove the segment back to positive organic growth.
Moderating Insurance Premiums Acting as Macro Catalyst
On the macro front, management highlighted that auto insurance premiums actually turned negative in May and June. Lower premiums improve consumer economics, decreasing the likelihood of total losses and structurally increasing the volume of repairable vehicles flowing into LKQ's ecosystem.
Aggressive Cost Reductions Offset Regional Weakness
Excluding the Germany ERP hit, management noted that aggressive cost-out programs in Europe successfully offset lower volumes in the UK and Benelux. While not enough to save the quarter's overall margin, these structural cost removals provide a leaner base for when volumes eventually normalize.
Strategic Review Remains in Limbo
The comprehensive strategic review (including the potential sale of the Specialty segment) remains active with 'no deadline or definitive timetable.' Given Specialty's margin deterioration this quarter, credit market uncertainty, and the stock's underperformance, a delayed or canceled transaction poses a risk to near-term catalyst expectations.
Other KPIs
Reversing. FCF for the first six months fell into negative territory (-$36M) compared to positive $186M in H1 2025. While Q2 alone generated $60M, the poor start to the year drastically limits the capital available for aggressive share repurchases, although LKQ did manage to buy back $52 million in stock during the quarter.
Accelerating. Up 5.0% YoY (4.5% organic), continuing its streak of positive growth despite heavy macro pressure on discretionary consumer spending. However, the victory is hollowed out by plunging profitability.
Guidance
Decelerating sharply. Management slashed the midpoint from $3.05 to $2.75, representing a near 10% reduction. This reflects the realization that European execution issues and broad margin compression cannot be resolved in the back half of the year.
Reversing to contraction. The previous guidance implied a return to growth (midpoint +0.5%). The updated guidance (midpoint -2.0%) confirms that the European collapse will mathematically outweigh the fragile North American recovery for the remainder of the year.
Decelerating. Cut by $75 million at the midpoint (from $775M to $700M). This directly constrains LKQ's ability to execute debt paydowns and buybacks simultaneously while maintaining its dividend.
Key Questions
ERP Disruption vs. Structural Share Loss
How much of the 12.6% organic revenue collapse in Europe was strictly due to the days the German ERP system was offline versus permanent customer defection to competitors during the outage?
Negative Operating Leverage
North America and Specialty both grew organic volumes, yet both saw EBITDA margins compress by over 140 basis points. What exactly is breaking the historical volume-to-margin correlation?
Capital Allocation Triage
With the free cash flow guidance slashed to $700M at the midpoint and $154M already committed to H1 dividends, how will LKQ prioritize the remaining capital between debt management and share repurchases if the Specialty sale process stalls indefinitely?